Read our latest updates & insights

On 5 February 2024, Rani Therapeutics published positive topline results from its phase I clinical trial regarding RT-111, a RaniPill® capsule containing Celltrion’s ustekinumab biosimilar, CT-P43 (biosimilar to Janssen’s Stelara®).  The study shows that RT-111 was well-tol...

On 5 February 2024, Novartis announced that it has agreed to acquire MorphoSys AG, a biopharmaceutical company focused on oncology medicines, for around €2.7B.   Upon completion of the acquisition, notably, Novartis would add to its portfolio the ‘next generation medi...

On 5 February 2024, Glaxo Smith Kline (GSK) announced results from an interim analysis of its DREAMM-7 phase III trial.  The trial compared two treatment combinations, namely: 

Blenrep® Combination: Blenrep® (belantamab mafodotin) +  BorDex® (bortezomib plus dexame...

On 5 February 2024, Ultimovacs announced that the FDA has granted a fast-track designation to its therapeutic cancer vaccine UV1 in combination with nivolumab and ipilimumab.  This was supported by the results of a phase II clinical trial for the treatment of patients with ...

On 5 February 2024, Novo Nordisk’s parent company Novo Holdings announced that it will acquire global contract development and manufacture company Catalent for USD $16.5B.  

Novo Holdings will secure 50 global sites in the acquisition and intends to sell three fill-f...

Novo Nordisk settled two lawsuits over counterfeit versions of Ozempic® (semaglutide) and Wegovy® (semaglutide).  The two companies involved, Cosmetic Laser Professionals Med Spa and Nuvida RxWeight Loss are permanently banned from claiming that their products are approved ...

Incyte has announced it has entered into an asset purchase agreement with MorphoSys, giving Incyte exclusive global development and commercialisation rights to tafasitamab, to be marketed in the US as Monjuvi® and outside the US as Minjuvi®.

In a previous agreement, ...

A study published in Medicina, on 4 February 2024, concluded that Rituximab represents an “efficacious and well-tolerated therapeutic option” for the management of Autoimmune Bullous Diseases (AIBD) and warrants consideration in cases of refractory AIBD.  

Regeneron announced that its marketing authorisation application (MAA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM), was accepted for review by the European Medicines Agency (EMA).  The MAA is supported by data from a Phase ...